Blood Reviews RSS feed: Articles in Press. This respected International journal, Blood Reviews , is a vital information resource, bringing together appraisals of clinical practice, and research from recognized experts. Specially commissioned articles from leading researchers and practitioners guarantee truly global coverage of all the sub-specialties of hematology. Blood Reviews publishes review articles covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the editors welcome suggestions from potential authors. They should first write a brief outline of an intended review and send this to Dr Trevor Baglin or to Dr Jacob M Rowe. http://www.bloodreviews.com//inpress?rss=yesElsevier Inc.en © 2010 Elsevier Ltd. All rights reserved. Blood Reviews0268-960X2010-09-06 © 2010 Elsevier Ltd. All rights reserved. healthpermissions@elsevier.comhttp://www.bloodreviews.com/article/PIIS0268960X1000041X/abstract?rss=yesAbstract: Myeloproliferative disorders are commonly associated with thrombohemorrhagic manifestations. The current review highlights recent advances in understanding the epidemiology and pathogenetic mechanisms of thrombotic and bleeding complications. Therapeutic modalities and prophylactic interventions corresponding to the specific disease states are also discussed.Thrombohemorrhagic complications of myeloproliferative disorders - Corrected ProofEmmanouil Papadakis, Ron Hoffman, Benjamin Brenner10.1016/j.blre.2010.08.002Blood Reviews (2010)2010-09-06Blood Reviews2010-09-06REVIEWhttp://www.bloodreviews.com/article/PIIS0268960X10000408/abstract?rss=yesAbstract: Most infants with birth weight <1.0kg are given multiple red blood cell (RBC) transfusions within the first few weeks of life. The anaemia of prematurity is caused by untimely birth occurring before placental iron transport and fetal erythropoiesis are complete, by phlebotomy blood losses taken for laboratory testing, by low plasma levels of erythropoietin due to both diminished production and accelerated catabolism, by rapid body growth and need for commensurate increase in red cell volume/mass, and by disorders causing RBC losses due to bleeding and/or hemolysis. RBC transfusions are the mainstay of therapy with recombinant human erythropoietin largely unused because it fails to substantially diminish RBC transfusion needs — despite exerting substantial erythropoietic effects on neonatal marrow.Anaemia of prematurity: Pathophysiology and treatment - Corrected ProofRonald G. Strauss10.1016/j.blre.2010.08.001Blood Reviews (2010)2010-09-03Blood Reviews2010-09-03REVIEW